<SEC-DOCUMENT>0001140361-21-027552.txt : 20210809
<SEC-HEADER>0001140361-21-027552.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210809161107
ACCESSION NUMBER:		0001140361-21-027552
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKET PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		211156583

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		646-440-9100

	MAIL ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOTEK PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20040226
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10027803_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:rckt="http://rocketpharma.com/20210809" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_7a0957213d7c45a5b54cb72494c8cbc3" contextRef="c20210809to20210809" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_16da9c080de84ea8bdc42e19eac843ef" contextRef="c20210809to20210809">0001281895</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rckt-20210809.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210809to20210809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-09</xbrli:startDate><xbrli:endDate>2021-08-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div>UNITED STATES</div>
</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, DC 20549</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_bc92f4ce798b499fb3b20874d5d1aa51" contextRef="c20210809to20210809">8-K</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to Section 13 or 15(d) of</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">The Securities Exchange Act of 1934</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_653efbaf631f4ced99d4b8f70af332d8" contextRef="c20210809to20210809" format="ixt:datemonthdayyearen">August 9, 2021</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_7538917290cd408591d23ac91eb7244b" contextRef="c20210809to20210809">Rocket Pharmaceuticals, Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_e2f1a4703bdf472090f7e1b57aa364db" contextRef="c20210809to20210809" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_54d297467ecc46e58083fcf0f440bfc4" contextRef="c20210809to20210809">001-36829</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_c92da0733544470388bab757f0643d9c" contextRef="c20210809to20210809">04-3475813</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Commission File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_85e2c03e16ec443b9455c60e260d832e" contextRef="c20210809to20210809">9 Cedarbrook Drive</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_3ee39cf79ce04e3194ad6657f9dde7a8" contextRef="c20210809to20210809">Cranbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_924c38fb290f48e2b987254d35460d7f" contextRef="c20210809to20210809">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_40705dc76281421584c8f80705d2c90b" contextRef="c20210809to20210809">08512</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of principal executive offices, including zip code)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_c3adc1c8d28e4022b3be15bcddb87438" contextRef="c20210809to20210809">646</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_9b1a985c7e0a4f808ef977ef36ec6685" contextRef="c20210809to20210809">440-9100</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s telephone number, including area code)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not applicable</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Former name or former address, if changed since last report)</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
      (see General Instruction A.2):</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 25pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_c8e65d5fe52148ea86c84e1129146ade" contextRef="c20210809to20210809" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 25pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_7b475d87d96e4ec9add72699c2acfc63" contextRef="c20210809to20210809" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 25pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_366a687a6f21459582124d474e11dc1c" contextRef="c20210809to20210809" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 25pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_972977fe870e4d30871cc39b632848ef" contextRef="c20210809to20210809" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="text-align: left; font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman'; white-space: nowrap;">
            <div style="text-align: left;">Title of each class</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Trading</div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Symbol(s)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e5b2162b5aa640beaaed0ad627f1413f" contextRef="c20210809to20210809">Common stock, $0.01 par value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_ecffefbba4a640f59ca2c7bd203a7abb" contextRef="c20210809to20210809">RCKT</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6e8bf94bc8e1435ba86bc858cbf5a401" contextRef="c20210809to20210809" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2
      of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_bebd3a169f1e4cfa845aa75a3bc3b6c8" contextRef="c20210809to20210809" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="text-align: left; font-size: 10pt; font-family: 'Times New Roman';"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="color: rgb(0, 0, 0);"> &#9744;</span></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> <br />
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div><span style="color: rgb(0, 0, 0);"><br /></span></div>
</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 2.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Results of Operations and Financial Condition.</div>
          </td>

  </tr>


</table>
    <div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On August 9, 2021, Rocket Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended June 30, 2021. A copy of the
        press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed
        &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange<span style="text-decoration: underline;">&#160;</span>Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
        Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</div>

    </div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';">
      <div><br />
      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
    </div>

    <div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(d) Exhibits.</div>

      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </div>

    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);"><a href="brhc10027803_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);">Press Release, dated August 9, 2021</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);">104</div>
          </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <div style="text-align: left; text-indent: 20pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Rocket Pharmaceuticals, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 46.97%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);">Date: August 9, 2021</div>
          </td>

    <td style="width: 3%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; color: rgb(0, 0, 0);">By:</div>
          </td>

    <td style="width: 46.97%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left;">/s/ Gaurav Shah, MD</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 46.97%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left;">Gaurav Shah, MD</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 3%; vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 46.97%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
            <div style="text-align: left; font-style: italic;">Chief Executive Officer and Director</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>

    <div>
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </span></div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10027803_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: left;"><a name="z_Hlk63949140"></a></div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 99.1<br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <img width="228" height="83" src="image0.jpg"></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress</div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; color: #000000;">&#8212;</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; color: #000000;">Working with FDA on Changes to Clinical Trial Protocol in Danon Disease Trial; Rocket Anticipates Trial Will Resume in 3Q&#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212;</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Increasing and
        Durable Benefit Observed in Low Dose Cohort (6.7e13 dose) in Danon Disease; Removing Higher Dose Cohort (1.1e14 dose) From Future Dosing Plans; Full Clinical Update Expected in 4Q &#8211;</font></div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212;</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Positive
        Results from FA, LAD-I, PKD Trials Presented at 24<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> ASGCT Annual Meeting Show Preliminary Evidence of Activity and Favorable Tolerability &#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212;</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Clinical
        Updates in FA, LAD-I, PKD and IMO Also Expected in 4Q &#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212;</font> <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Ending Balance
        Sheet with $426.8 Million in Cash; Cash Runway Expected into 2H'23 &#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#8212;</font> <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Conference Call
        to Be Held at 4:30 p.m. ET Today&#8212;</font></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CRANBURY, NJ </font>&#8211; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Aug. 9, 2021 </font>&#8211; <u>Rocket Pharmaceuticals, Inc.</u> (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare
      childhood disorders, today reports financial results for the quarter ending June 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;We are grateful to the FDA for its support and for working with us on our Danon program toward resuming our trial, which we believe will
      occur in the third quarter,&#8221; said Gaurav Shah, M.D., chief executive officer of Rocket Pharma. &#8220;Further, we have observed durable clinical benefit in the low dose adult cohort, which we believe is supportive of its potential as a viable Phase 2 dose.
      As of July 2021, we see improvement in two of three low dose patients in NYHA class. In these two patients, we also observed substantial improvement of a key marker of heart failure, BNP, which decreased from a pretreatment baseline by 75 percent in
      one patient and 79 percent in the other as well as improvement in cardiac output by 35 percent in one patient and 62 percent in the other as measured by invasive hemodynamics. The third patient has demonstrated stabilization of NYHA class and BNP.
      Given the positive benefit/risk profile in the low dose, and additionally to mitigate safety concerns observed at the higher dose, in agreement with FDA we will no longer treat Danon patients with the higher dose (1.1e14). With our full focus on the
      low dose, we look forward to progressing our trial on behalf of Danon patients devastated by this disease.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Shah continued, &#8220;We also presented positive data across three of our lentiviral-based gene therapy programs at ASGCT in May, which we
      believe support the growing potential of these programs to treat Fanconi Anemia (FA), LAD-1 and PKD patients. Based on these results, we continue our momentum toward advancing these programs. In the case of our FA program, two recent publications
      reinforce the natural history, clinical design and methods being utilized in our Phase 1/2 FA trial of RP-L102. We look forward to providing updates on all five of our programs in the fourth quarter of 2021.&#8221;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img width="228" height="83" src="image0.jpg"></div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Shah added, &#8220;Finally, and importantly, we are deeply saddened that the first patient dosed in our Phase 1 IMO trial, has passed way from
      pulmonary hemorrhage related to thrombocytopenia following conditioning therapy and also related to underlying osteopetrosis. This event was considered likely not related to RP-L401 gene therapy. Consistent with the trial protocol, enrollment has
      been temporarily paused pending a comprehensive evaluation in collaboration with the Independent Data Monitoring Committee, which will include a review of the conditioning regimen and other potential safety measures to mitigate the impact of
      underlying disease on treatment. This outcome underscores the need to find cures for this devastating disease and has furthered our commitment and dedication to patients and our mission to develop curative gene therapies for rare disease.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Key Pipeline and Operational Updates</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><u>Danon Disease:</u></div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z636e22ef5aae476fae9384389ca94c92">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Progressed toward agreement with FDA on changes to the Phase 1 clinical
                trial protocol in Danon Disease. Rocket anticipates trial may resume this quarter. </font>The <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">U.S. Food and Drug Administration (FDA) </font>had
              previously requested Rocket pause patient dosing in the Phase 1 clinical trial of RP-A501 and modify the protocol and other supporting documents with revised guidelines for patient selection and management. No new drug-related safety events
              were observed in the low- or higher-dose adult cohorts; the previously disclosed SAE of thrombotic microangiopathy, which has since resolved, was reclassified as a SUSAR. All follow-up study activities continue. Longer-term results from the
              low (6.7e13) and higher dose (1.1e14) adult cohorts will be reported in the fourth quarter. In agreement with FDA, Rocket will no longer continue dosing patients at the higher dose (1.1e14).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><u>Fanconi Anemia (FA):</u></div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59eda6c4c58f4f2890fdcfeb2aa9633a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Presented positive clinical updates from RP-L102 Fanconi Anemia (FA)
                program at ASGCT. </font>Preliminary results from the Phase 1 and 2 trials presented in a poster at ASGCT are from nine pediatric patients. For RP-L102, Rocket&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ex vivo</font> lentiviral gene therapy candidate for FA, increasing evidence of engraftment was observed in at least six of the nine patients, including two patients with at least 15-months of follow-up and four
              patients with at least 6-months of follow-up. A highly favorable tolerability profile was also observed with all subjects being treated without conditioning and with no reports of dysplasia. One patient experienced a Grade 2 transient
              infusion-related reaction. The full data presented are available <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>here</u></font>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f0c346940364f76840dce7c4213578a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Published two peer-reviewed studies supporting the natural history and
                clinical design of FA clinical trial. </font>&#8220;Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients&#8221; was published in the <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">American Journal of Hematology</font>. Data strengthen the natural history of Fanconi Anemia and indicate that reverse mosaicism is a good prognostic factor in FA and is associated with more favorable long-term
              clinical outcomes. FA mosaicism in hematopoietic cells is a biologic and clinical proof-of principle for autologous gene therapy in FA patients and results provide a compelling rationale for continued clinical evaluation of autologous gene
              therapy. Additionally, &#8220;Improved Collection of Hematopoietic Stem Cells and Progenitors from Fanconi Anemia Patients for Gene Therapy Purposes&#8221; was published in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Molecular Therapy: Methods &amp; Clinical Development</font>. Results demonstrate the safety and efficacy of filgrastim and plerixafor for mobilization of hematopoietic stem and progenitor cells (HSPCs) and collection
              by leukapheresis in FA patients, offering crucial information for the enrollment of FA patients for gene therapy studies.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img width="228" height="83" src="image0.jpg"></div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><u>Infantile Malignant Osteopetrosis (IMO):</u></div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59fad94877254087ab74cc8dec28fae8">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">First patient dosed in the RP-L401 Infantile Malignant Osteopetrosis
                (IMO) Phase 1 clinical trial passed away from likely non-RP-L401 gene therapy related pulmonary complications.</font>&#160; IMO is a bone marrow-derived disorder associated with severe bone and hematologic manifestations leading to death in the
              first decade of life, frequently within the first two years of life, without an allogenic hematopoietic stem cell transplant (HSCT).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The first patient in the Phase 1 study, a six-year-old child with severe IMO-related anemia and bone abnormalities, was infused with
      RP-L401 without immediate complications. During the initial weeks after therapy, the patient died of pulmonary complications, most likely pulmonary hemorrhage related to thrombocytopenia following conditioning therapy and also related to underlying
      osteopetrosis. <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Pulmonary hemorrhage is a rare but documented complication of HSCT, and pulmonary complications, including life-threatening and fatal
        complications, have been observed to occur with high frequency in osteopetrosis patients undergoing allogeneic HSCT procedures.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The patient death is not considered to be RP-L401-related by study investigators and as corroborated by autopsy findings. In accordance
      with the trial protocol, enrollment has been temporarily paused pending a comprehensive evaluation in collaboration with the Independent Data Monitoring Committee.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><u>Leukocyte Adhesion Deficiency-I (LAD-I):</u></div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z21aee57037c6418fa4b398c877aaec0c">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Presented positive clinical updates from RP-L201 Leukocyte Adhesion
                Deficiency-I (LAD-I) program at ASGCT. </font>Phase 1/2 data presented in an oral presentation at ASGCT are from four pediatric patients with severe LAD-I. RP-L201, Rocket&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ex-vivo</font> lentiviral gene therapy candidate showed preliminary activity in all four patients, including one patient with 18-months of follow-up and one patient with 9-months of follow-up. CD18
              expression substantially exceeded the 4-10% threshold in all four patients, which is associated with survival into adulthood and consistent with the reversal of severe LAD-I phenotype. Most importantly, all four patients were able to leave
              the hospital in the weeks following RP-L201 therapy. The full data presented are available <u>here</u>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><u>Pyruvate Kinase Deficiency (PKD):</u></div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae54eed7fb3a47fe8025c5c0fd7c0a6e">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Presented positive clinical updates from RP-L301 Pyruvate Kinase
                Deficiency (PKD) program at ASGCT. </font>Updated preliminary Phase 1 data presented in an oral presentation at ASGCT are from two patients with significant anemia and transfusion requirements that showed sustained tolerability.
              Preliminary activity, measured by peripheral blood VCN levels, was observed in both patients during the initial 9-months and 3-months post-treatment, respectively. Durable normalization of hemoglobin levels were observed, from an average
              baseline of ~7.4 grams (g)/deciliter (dL) to 13.1 g/dL at 9-months post treatment in the first patient and from a baseline of ~7.0 g/dL to 14.4 g/dL at 6-months post treatment in the second patient. The Phase 1 trial continues to enroll
              patients with longer-term data expected in the fourth quarter. The full data presented are available <u>here</u>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img width="228" height="83" src="image0.jpg"></div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Anticipated Milestones</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9082cb8eae354d549b457f987b83645d">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fanconi Anemia (RP-L102)</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0fd199e536c476a83f44662b93309ee">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Updated &#8220;Process B&#8221; data (Q4 2021)</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zda467fc42081419f897313082244fe46">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">LAD-I (RP-L201)</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5dd97b17d5a840fbba6a4d96c53150b2">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Longer-term Phase 2 data (Q4 2021)</div>
            </td>
          </tr>

      </table>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z80f46b57d2e34d20be424739348090e2">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Danon Disease (RP-A501)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72100f44d9644afcb33538d4fb80d7e8">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Longer-term Phase 1 data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9045f679359493cb11ede3b94b0f8be">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PKD (RP-L301)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72d270c84f1b43a1861f35c8c8ab50a7">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Longer-term Phase 1 data (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za402dc436e2e4637b13080b186ed1680">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">IMO (RP-L401)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5df705fe15b34ed18c435b1740ec5893">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 1 clinical update (Q4 2021)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Upcoming Investor Conference</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z38151c453c9f4198991644087fc9bf87">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Citi&#8217;s 16<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual BioPharma Virtual Conference, Sept. 8-10, 2021</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second Quarter Financial Results</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05b4eb5db2124e3b955284f0b617c0f5">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cash position. </font>Cash, cash equivalents and investments as of June
              30, 2021 were $426.8 million.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd3040799d7834b109ec246a1877d278d">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">R&amp;D expenses. </font>Research and development expenses were $24.8
              million for the three months ended June 30, 2021, compared to $16.7 million for the three months ended June 30, 2020, due to an increase in compensation and benefits expense resulting from increased R&amp;D headcount, an increase in non-cash
              stock compensation expense, an increase in manufacturing and development costs, and an increase in clinical trials expense.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zecdc647c1a524fcc8faa30e1ca430212">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">G&amp;A expenses. </font>General and administrative expenses were $9.3
              million for the three months ended June 30, 2021, compared to $6.8 million for the three months ended June 30, 2020, due to an increase in non-cash stock compensation expense, an increase in compensation and benefits expense due to increased
              G&amp;A headcount and an increase in office and administrative costs.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5b3fce53e45e4bf7b7fb57fae34909f9">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Net loss. </font>Net loss was $34.5 million or $0.55 per share (basic
              and diluted) for the three months ended June 30, 2021, compared to $25.0 million or $0.45 per share (basic and diluted) for the three months ended June 30, 2020.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zab5136e6927f4eee89b91c4f3766066a">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Shares outstanding. </font>63,448,069 shares of common stock were
              outstanding as of June 30, 2021.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Guidance</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z443a472641734966b79dd1abcfe71c60">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rocket expects its balance in cash, cash equivalents and investments of $426.8 million as of June 30, 2021 to fund its operations into the second half of 2023,
              including the continued buildout and initiation of AAV cGMP manufacturing capabilities at our Cranbury, New Jersey R&amp;D and manufacturing facility and continued development of our five clinical programs.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img width="228" height="83" src="image0.jpg"></div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Conference Call Details</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rocket management will host a conference call today at 4:30 p.m. ET. To access the call and webcast, please visit the events section of the <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>website</u></font>. The webcast replay will be available on the Rocket website following the completion of the call.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investors may access the conference call by dialing (866) 939-3921 from locations in the United States or +1 (678) 302-3550 from outside the United States.
        Please refer to conference ID number 50210581.</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Rocket Pharmaceuticals, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (&#8220;Rocket&#8221;) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of
      complex and rare childhood disorders. The company&#8217;s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical
      programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe
      pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to
      life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket&#8217;s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure
      condition. For more information about Rocket, please visit <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>www.rocketpharma.com</u></font>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Rocket Cautionary Statement Regarding Forward-Looking Statements</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding
      its guidance for 2021 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile
      Malignant Osteopetrosis (IMO) and Danon Disease, the actions of the FDA regarding the clinical hold on Rocket&#8217;s Danon Disease program and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute
      forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not
      place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the
      negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these
      forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees,
      the interest from patients and families for participation in each of Rocket&#8217;s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations
      regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third
      parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's
      Annual Report on Form 10-K for the year ended December 31, 2020, filed March 1, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket
      undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img width="228" height="83" src="image0.jpg"></div>
    <div style="text-align: left; margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Selected Financial Information</div>
    <div style="text-align: left; margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating Results:</div>
    <div style="text-align: left; margin-left: 5.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(amounts in thousands, except share and per share data)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" class="cfttable" id="zcc3f42531a9d4be9a55731b154fe9a7c" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-left: 45pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Six Months Ended June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-left: 45pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> 2021</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2020</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2020</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Operating expenses:</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">Research and development</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24,798</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,731</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,340</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">33,687</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 18pt;">General and administrative</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,250</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,828</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,930</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,990</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Total operating expenses</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,048</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,559</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73,270</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47,677</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Loss from operations</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(34,048</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23,559</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(73,270</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47,677</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Research and development incentives</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Interest expense</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(251</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,786</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,980</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,360</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Interest and other income net</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">501</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">429</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,412</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,395</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Amortization of premium on investments - net</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(727</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(124</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,366</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(62</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(34,525</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25,040</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(74,704</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(49,704</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss per share attributable to common shareholders - basic and diluted</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.55</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.45</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.20</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.90</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Weighted-average common shares outstanding - basic and diluted</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,061,232</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55,158,459</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62,321,926</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55,020,789</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; text-indent: -9pt; margin-left: 9pt;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; text-indent: -9pt; margin-left: 9pt;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> June 30,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="2" style="vertical-align: bottom;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">December 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; text-indent: -9pt; margin-left: 9pt;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" rowspan="1" class="cftcurrcell" colspan="2" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; text-align: center;">2021</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" rowspan="1" class="cftcurrcell" colspan="2" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold; text-align: center;">2020</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Cash, cash equivalents and investments</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">426,830</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">482,719</div>
          </td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total assets</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">535,154</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">590,824</div>
          </td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total liabilities</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,717</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,305</div>
          </td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftguttercell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;">&#160;</td>
          <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
          <td class="cftnumcell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 9%; text-align: right;">&#160;</td>
          <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 52%;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Total stockholders' equity</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">489,437</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">503,519</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftcurrcell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contacts:</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z03a7e4b839634eaa94ca0f5adb218cd7">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>Media</u></div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>Investors</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Kevin Giordano</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mayur Kasetty, M.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director, Corporate Communications</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director, Business Development &amp; Operations</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>kgiordano@rocketpharma.com</u></div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>investors@rocketpharma.com</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rckt-20210809.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://rocketpharma.com/20210809" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:rckt="http://rocketpharma.com/20210809" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20210809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20210809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rckt-20210809_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rckt-20210809_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rckt-20210809.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://rocketpharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V!WX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKLHXC[,CY_'Y7:]2BOD>H44R*:.>,21.'0]".]/KK/"V"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'RM>A.A/DF@HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***.U '@OC+4KJ_\ $=U'/)E(9"B#
ML #7/>U:OB0?\5+J''_+=OYUE>_>O)F[R;9]Q0BHTHI=D'.>*/KTH[\"E_#C
MUJ383^?:CG&*/PH[9QS0 ?2CZ]*._ I?PX]: $_GVHYQBC\*.V<<T 'TH^O2
MCOP*7\./6@!/Y]J.<8H_"CMG'- !]*/KTH[\"E_#CUH 3^?:CG&*/PH[9QS0
M ?2CZ]*._ I?PX]: $_GVHYQBC\*.V<<T '/K1SZBCOP*7VQQZT (-RL&5BK
M Y!!KZ"\*WDE]X>M)I6W.8QD_A7S[^'TKWCP/_R*UIQ_ /Y5TX5^\>-G44Z,
M7V9S'Q4U!HUM;-'(W LX!ZBO+N0.HQ7H/Q5_Y"]K_P!<J\__  XJ*[O49U99
M%+"QL)]:7Z&D_G2_AS6)WB?Y-'X\4?Y-+^'% "?7K1SZ\T?SI?PYH 3_ ":/
MQXH_R:7\.* $^O6CGUYH_G2_AS0 G^31^/%'^32_AQ0 GUZT<^O-'\Z7\.:
M$_R:/QXH_P FE_#B@!/KUHY]>:/YTOX<T )_DT?CQ1_DTOX<4 )]>M'.>HH_
MG2_AS0 ?PDYZ5ZM\,=2:6Q:T=B2G3)KRC\.*]&^%W_'U-Q6V'?[Q'G9I%/"R
M;Z6_,]5HHHKTCY(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>!_^16M.?X!_*NG#?&>1G/\  7J<1\5?^0O:_P#7*O/L=N:]!^*O_(7M>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[\T?Y-+^/% ">WK1[<T?SI?QYH 3KSZ49[\T?Y-+^/% ">WK1[<T?SI?QYH
M3KSZ49[\T?Y-+^/% ">WK1[<T?SI?QYH 3W]*]&^%W_'U-UKSGWSQ7HWPN_X
M^IN:VH?Q$<&9_P"ZS^7YH]5HHHKTCY **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCI^-'M0 =1SV[5[QX'_Y%:TX_@'\J\'ZC/I7O'@?GPM:?[@_E73AOC/(SG^
MO4XCXJ_\A>U_ZY5Y]CMBO0?BK_R%[4?],J\^]N:BO_$9TY=_NL/ZZA_2CWQS
M1UY]*,]^:Q.X/:C';%'MZT>W- !_2CWQS1UY]*,]^: #VHQVQ1[>M'MS0 ?T
MH]\<T=>?2C/?F@ ]J,=L4>WK1[<T ']*/?'-'7GTHSWYH /:C';%'MZT>W-
M!_2CWQS1UY]*,]^: #VHQVQ1[>M'MS0 ?TH]\<T=>?2C/?F@ ]L<&O1OA</]
M*FXKSGV]:]&^%W_'U-UK:A_$1P9G_NL_E^:/5:***](^0"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUZ-\+O\ CYFYKSG^?:O1_A</](F/YUM0_B(X,S_W6?R_,]4HHHKTCY ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY[B*VB:69PB*,DFJ.N
MZU:Z#I4U]=R!$121GN<5\T>)OB#KGB6<[IWMX02 D38##WHN-(^B'\=>&HW*
M/JUN&'4;JT=-US3=7!-A=QSX&3L-?'+('8EE#-W)[U>TW5]2TB5);"[E@VL"
M51L!O8TKCL?9%%<#\.?'Z^++9H+HHE[$H+(*[ZF2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I"<#/I2U4U2<6VE74Y. D3-G\* / _C#XJ&KZK
M%I<#GR+8DN >"W:O,O;%3WMRUY?SW$A.YW/\Z@_&I*0?A2\>G%)^-'XT#-/P
M_JUQHNMVUY;N4VN-Q'<9KZVTV]CU'3X;J)@RNH.17QM^-?17P;UE]2\-O;OG
M-O@<^^::$STJBBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB.BX6/IBBH;2ZBO;6.X@</'(H92/0U-3$%%%% !1110 4444 %%%% !1110
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MU/I[5A_UI>W6FFT[HFI3C4CRR5TSZ"T+Q'8Z];"6V?#=T;J*T+RSAOK62"=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+OQ/D:3QQ<[N=N0
M,_6OJ*OEKXF_\CO=\9.3_.DQHY'KZ<4>_%)^%'OCBD4+T].:/;BD_"CVQS0!
MM>$K@VOBBQF'57KZXC.8D/JHKY \/_\ (>L^/^6@KZ^B_P!2G^Z*:)8^BBBF
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M H^E(0",$#%'3CUHP.E '3>&/&5]H,GD,WF6K'D.<[ /2O:-,U2UU:S2YM9
MR, >O-?./7\*U=$U^]T&Y\RVD81L1O6NBE7<-'L>7CLMC77/#27YGO.HZ7::
MI!Y5W D@QQN&<5XQXK\(W&@W1>*-GM&Y#8R0:]:T#Q)9:]:K)!(!)_%&3\PK
M6F@CGC*2HK*1C!%=4Z<:JNCQ</BJN#GRR6G8^:,GT&:M6&FWFJW2V]E%OD;O
MCBO2=4^&23WK2V91(V.2":[#0/#MEH-IY5M$ S<NQ]:YHX>3E9['L5LVI1I\
MU/5F9X6\&66B6JR2Q"6Z;#%G&2A]!72W%U#:1&29U10,\FJNJZS9Z/;F6ZF1
M3C(4GDUXKXI\47'B"\W*[K;H3L7.*Z)SC25D>50PU;'5.>;T[_Y&EXN\;W.J
MW#6UC*4ME)&Y3@M7&8YS^9HXR*/?%<$I.3NSZ:C1A1@HP5@YSQ1]>E'3CUHP
M.E2:A_/M1SC-'7\*/?% !]*/KTHZ<>M&!TH /Y]J.<9HZ_A1[XH /\FC\.*/
M;UHXZ8H /KUHY].:/?THXZX- !_DT?@*.G'K1QTQ0 <YI1G' %)[^E'O@T 7
MM*UB]T2[2XLI&4 Y:,'"M]:]H\*^*[?Q!:?,ZK<J!O3.*\)Z<>M36MU/97*7
M%L[)+&<J0>,UK2JN#\CAQF!AB8]I=SZ2EBCFC:.5 Z,,%2.#7F?C;P,$4W^E
M0 8!+QJ, "M;P=XYBU5!:W\@2Z! !8XW'VKN" PP0"#7:U"M$^>C*O@*MG_P
M&?,S!D8JZE2#R",4J(\CB.--S,<* ,U[3XG\#VVM.)X$6.?&">@IOACP+;:+
M+]IN$62X4_*>H%<OU:7-;H>U_:U'V7/U[&#X*\!'*W^K1893E(SR"*].CC2*
M-4C4*JC  [4X  8 Q17;"FH*R/GL3BJF(GS3"BBBK.<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/B!_R)FH
M_P#7%OY5T]<Q\0/^1+U'_KBW\J /E(9Z8'%+[X%-'3H<TO'IQ4E!R.PYI<'I
MBD_"CMTH&')[#BO:?@/R=1^BUXM^%>T_ ?KJ..F%H0F>UT4451(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWM)B%D7.<#/:OI[3M2MM5M$N;60/&PSP:HEENBBB@ HHHH *YCX@?\B9J/\
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M[_SI?RQ0 G]:/;/-'\Z7G';- ">]&>^:._\ .E_+% "?UH/W2,T?SH.=O;-
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M/?I1[URGM!T[=:/;M1P.YYH]J #KVZ4>_>C@]^E'O0 =.W6CV[4<#N>:/:@
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M?NDXI>O/I0<;2<T >V_#L8\.+_O?TKKJY'X=\>'%_P![^E==7J4O@1\7C?\
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MM#>V\B.IP<*<4 4OPH_#FC(/<T?C0 ?A1[XXH_$TOX\4#$_"C\.:./4T=LT
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M(D,:[I'8*H'<F@#:\*>';SQ'K<%K;QDQJX,C8X SS7U?86<5A916T*!41<8
MKE?AOX37PSX;B6:("\ER\C$<\]J[.FB6%%%%,04444 %%%% !7!?%7Q,FA>&
M9($DQ<W(,:J#R 1UKO"< GTKYD^*^KMJOC:95DW0VR"-0#QGK_6DQHX<9QG(
MYZT<],BEY]!2<],"D4+^/2DR>N12_ATI.>N!0 OX]: &9@B_,Q. !W-'2O5?
M@_X,74[PZU?6X>VCR(U89!:@3-CX7?#@)%'K.L6V)3DQ1N.5^HKV1(TC0(BA
M5'0 8I0 J@ 8 & *6J)"BBB@ HHHH *KWEE;WUNT%Q$KHPP01FK%% 'SI\2_
MAW+X?NFU+3(2=.8X9%&2I/<UYL"3SD5]FW=I!?6LEM<1K)%(,,K#(-?,WQ)\
M(?\ "+^(";>,_89AN5L< ^E)H:.,_'K2<],BE_K28/3 I%"_CTI,GKD4OX=*
M3GK@4 >A_![6QIOB\6LTNV&Y0KR> >O]*^D001D=#7QC:7#VEY%<(Q5D8$$5
M]:>$]6&M^&K._!!\Q,''MQ31+-JBBBF(*0@,,$ CT-+10!Q^O?#?P_KLK3W%
MJ/.)R"O K%_X4SX<SG[,?^^J]*HH'<\U_P"%,^'/^?8_]]5XIXRTB#0_$D]A
M; +$A.!^-?6M?+7Q-S_PF]V,=S_.DP1R/)[]*3GKD4O7MTI.>N!2*%Z=^M)S
MTR*7D=NM)STP* +NDVR7NJ6]O+RCN 17OB_!OPXP#"V/(S]ZO"?#_P#R'K/C
M_EH*^OHO]2G^Z*:)9YQ_PIGPY_S['_OJC_A3/AS&/LQ_[ZKTJBF%SB-%^%OA
MW1[Q;N.US,O"DG(Q7;*JHH50 HX  I:*!!1110 4444 %%%% !1110 4444
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MBCKSZ49[_I0 =./6C Z4=/QH]LT '7\*?#_KXCC^,?SIG7GTI\/_ !\1'/\
M&/YT ?25I_QYP_[@_E7@'B?_ )&74!C_ );-_.O?K3_CRA_W!_*O ?$_/B74
M!G_ELW\Z[<5\*/G,E_BS]#)Z_A1[XHZ\^E&>_P"E<1]&'3CUHP.E'3\:/;-
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MS75@8&!110 4444 %%%% !7,?$#_ )$O4?\ KBW\JZ>N8^('_(F:C_UQ;^5
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M7Z)I-MHFDP6%J@2.->GOWKR7X(>'@5GUR1<\F-,CITYKVJFB6%%%%,04444
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M'6CMG'- !WXI?Y4GL.]&/;CUH /\BCG';-'6CMG'- !WXI?Y4GL.]&/;CUH
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MX?XU^SZ?ZP5]?1?ZE/\ =%?(/A[C7[/C_EH*^OHO]2G^Z*:)8^BBBF(****
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MQLD=O$T*'[JKQ^0KS#\.:3*0OMQQ1[\4GX4?AQ2&+[\<TAX&.*/PI&^X>.:
M/H_X-V/V;P>DV/\ 7$G]37HU<C\,HQ'X!TW'4IDUUU40%%%% !1110 4444
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MH^<R7^+/T,GKSZ49'6CZ4?7I7$?1AT_&CVS1_/M1SC% !UY]*,CK1]*/KTH
M.GXT>V:/Y]J.<8H .O/I1D=:/I1]>E !T_&CVS1_/M1SC% ![^E''7-'^31^
M/% ![>M''3)H^O6CGUYH .O/I1QUS1_DT?CQ0 >WK1QTR:/KUHY]>: #KSZ4
M<=<T?Y-'X\4 'MZT'&TC)H^O6@YV]>: /;?AV<^'%_WOZ5UU<C\._P#D7%Q_
M>_I775ZE+X$?%XW_ 'B?J%<O\1/^1%U/_KG745R_Q$_Y$74_^N=:'*?*8Z=:
M./4T#/7-'/3(YJ2Q?QXI/Q-+[9I.>N1Q0 ?CS7M?P&($&ICU<5XKSUS7M7P&
MX@U/D<NM-"9[31113)"BBB@ HHHH **** "BBB@#Y_\ C:Q_MZ$;CC'3\*\K
M_'BO4_C:/^)_"<]OZ5Y;STR.:DI"?CQ1^/-+STR.*3GKD4##\>:1NG4TO/7(
MI&R%(R.: /I[X4JJ^!K+: ,J<^_-=O7$?"KCP+8_[I_G7;U2("BBB@ HHHH
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M1Q[X[T +[XKVKX##]QJ9(_C6O%./?%>U_ 8?N=3//#BFA/8]IHHHIDA1110
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M_P ,91)X"TT _=0C]:["J("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N8^('_(F:C_UQ;^5=/7,?$#_D3-1_ZXM_*@#Y2'3&.E+[XIH_
M'/>EX]\5)0OX=:,=L4GUS[48X[YH&+U[=*/?%)^?O1Q[XH 7\.M'MBDX[Y]J
M,?7- "]>W2CWQ2?G[T<>^* %_#K1[8I..^?:C'US0 O7MTH(]L4GYT8YX!H
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MZ^B_U*?[HKY!\/?\A^SZ_P"L%?7T7^I3_=%-$L?1113$%%%% !1110 4444
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MBE]^.:/;B@#Z'^"UY]H\*&'.?).,?B:],KQ+X$ZAF;4+ ]E#U[;31#"BBBF
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MHJ_110 4444 %%%% !1110 5\M?$W_D>+L9P,G^=?4M?+7Q-_P"1WNQQU/\
M.DQHY#\:/?/-+U].*/?BD4)^-'MGBE_+FCVXH TO#W_(?L^?^6@KZ^B_U*?[
MHKY!\/\ .O6?_705]?1?ZE/]T4T2Q]%%%,04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3ZLVE^+U0#"W"[#S[BOIFOC2PO'L-0M[J-F5HG#'%?6WAO45U7P[8WBG/F1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4R2-)4*2*&4C!!&:?10!Y7XP\ +;1R7^EQD@=85Y)KS@YRRL-K*<$>
MAKZ;(R,'O7!>,? D.H0M=Z;$$N1_ @P&^M<E;#]8GO8#-+6IUOO_ ,SR'KVZ
M4>_>I)H9+>=X9E9'1MI!%1GD\5QGT"U#IVZT>W:CIU-&0*0!U[=*/?O2Y]:3
MCK0 =.,9S3XHI;F588(R\C=%%3Z=IUUJMVMK:1EW8]<5[1X6\&V6A6JN\8EN
M6^8NXR5/H*UITG-G'B\;##1UU?8R_"/@*UL[>.]U!/-N& 90?X/:NIU?6K+0
M[3?,Z(0/D3IFJ'B;Q;9Z!!M,BFY8?(O6O%=6U>ZUF[>XNY6;<Q*H3POTKIG4
MC27+'<\>AA:V.G[6L_=_K8O^(O%%]X@NB9)&2W4G9&#C%88&*3('6NF\*>#[
MCQ#,LDJNEFIPS=#FN3WIR\SW6Z6&I]HHS]!T"[U^Y$<*LL0.&DQP*]K\/^&K
M#0+01V\*^:P!D<\Y/K5W3=+M=*M5@M8E0 #)48W'U-7:[J5%0U>Y\SC<PGB'
MRQTB%%%%;GG!1110 A (P0"/>N&\6> K;4PUW9@0W');'\5=U14S@I*S-J%>
MI0ES09\TW-O/:3-!<1F.13]TU%DCYAD'U!KW?Q)X0L=>B+L@2< X=1R:\5U7
M2KO1KQK>[C*MU''&*\ZK2=-^1]5@\=#$K31]CL?"/Q N;1TL-2;S(NB2'C8!
MVKUB":*Y@66)@\;C(([U\T\'@UU7A;QI>Z'*+>60RVK'G><[ /2M:5=QTD<F
M/RQ5/WE'1]CT/Q1X(L];4S0@0W('WQWKQN_L;C3;IH+F-D<'C/<>M?0^G:E;
M:I:)<VT@=' /6L_Q!X8L=?MRL\867&!(!\PK6K04_>B<."S&>'?LZVWY'S_T
MX]:,=OUK3UO0[O0;YK>YC8*22C8ZKVK,P",9KA::=F?2QDII2B[H.OX4>^*.
M#SDT9'6D4'MZT>V*/;UI>V,F@!/?TH[C R3Q3D5I9%CC4L['  %>E^"O 95E
MU#5HOG5LI$>015PA*;LCGQ.)AAX<TS*\'>!Y=5E%WJ4;1VZ'_5-QO':O7+2S
MM[&W6"WC"1J,  5*B+&@1%"J!@ =J=7HTZ2@M#Y3%XRIB97EMV"BBBM#D"BB
MB@ HHHH **** "N7^(G_ "(NI_\ 7.NHKE_B)_R(NI_]<Z /E,?2C\*!]:/Q
M-26'X<T?A1^/-''J: #\.*]K^ H_<:F2/XQ7BOX\5[5\!N8=3.3PXIH3V/::
M***9(4444 %%%% !1110 4444 %<E\1](35O!M\NS=+''N0^F.:ZVH[B%;BW
MDA<9612I^AH ^,"I4E"/F4X-)^'%;_C32FT;Q;?VI7:GFDH/8\U@?CQ4EA^'
M%'X<T?CQ1^/- !^'-!Y'3CO1^/-'X\4 >P_"#QP()8] O&PC'$+,>G?%>YU\
M712O;SI-#(R2(<JZGD&OH;X:?$.#6["#3;^<#4$7;\Q^]CWIHEH]+HHZC(HI
MB"BBB@ HHHH *;)(L4;2.0JJ,DGM2E@H)8@ =237BWQ7^(>T-HNDW'S@D3NA
MY'XT <G\4_%TOB#7WL89,V5H^%VG@GUK@>,=*,DG)8ECR2>]'%24'X4?AS1Q
MZFC\>:!A^%'X<4?B:7V[4 +%$9YXX5!S(P45]:>#--&E>$M.M>-RQ DX[FO
M?A7H0UOQ8I>/?%;+O.1QG-?3:JJ*%4 *!@ =J:)8M%%%,04444 %><?&/1?[
M3\++.HR]L^_CTQ7H]5KZSBOK*6VE4,DBD$$4 ?&:^XI?PYK7\4:<-)\4:A8[
M2HCE.T8['I63^-24)^%'X<4?0FE_'B@8GX48R.E''J:7/'6@#V7X.>-7#-H5
M_-^[1?W!8^_2O;NHS7Q=%-+;RK-!*\<JG(93@BOH'X8?$&/6;--,U&<"]B3
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M-Q ADC8=<@<5V5(RAT*L,@C!% 'Q9T+ CD'!H]\<5V_Q1\.+H'BR5K>/9:7
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M-8P2+R&C4C\J^,O?)XZ5]1_#774UKPA:X<-);H(FYYR!31+.QHHHIB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** .8\5>$K?7;-VBC1+H#Y&QBO%]1TR\TJY:*[A= #@,P
MP&^E?1]9&O:#;:[8O!,B^81\KD<K7/5H*>JW/5P.92H>Y/6/Y'SWSZ_2C\:V
MM=\,:CH,S>? Q@W820<YK%/3WK@::=F?3TYQFN:+N@]\C%:NA^'K_P 07BPV
MT9$9ZRD?*/:M#PSX,O\ 7IU>2,PV><F4_P L5[18V%GH]F(H52) /F/3)K>E
M0<M7L>;CLQC0]RGK+\BKH'A^ST&P6&"-0Y^9VQW[U@>+?'5MI:-:V4HDN2,;
MD.0I]#61XO\ 'Z$M8Z4Y8\AI1QM->:,S2.TCG+L<LWJ:TJUU%<L#DP>72JR]
MMB/N'W-U/>W3W$\A>1V)))J+=V)'/;UIT<<DTH2*,NQ.  *]1\'> 1"@N]6A
M4N<;8FYQ[USP@ZCLCUL1B:>&A>7R1D>#O <FI?Z7JL++ &^6-A@GWKUJWMXK
M:%8H4"HHP !4BJ$4*HP , 4M>A3IJ"T/E,5BZF(E>6W8****T.4**** "BBB
M@ HHHH *S-8T*RUJW,5W$&XX..:TZ*32:LRHSE!\T79GS]XA\-7V@7;"2,F
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M%(H.1WZTG/3(I?PZT>V* $_&NP^'7B>7P]XCA#2[;:=@CC/')ZUR ^E R&#
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MX\?5@]E8;X[<'YF/!)]JSO%/B^[UV:6!6,=H&P$SU]ZYD#CUKCK5[^['8][
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M !1110 4444 %>0?%_P0+RU?7K-<S1#,BCN*]?J*YMX[NVDMYEW1R*58>H-
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M%)^'6CH.10 '\.*]3^%?@"35-076-2C*6T.&B0]6;/\ *L7X>^ 9_%=^MQ<
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M!A>:=B6SE/!GP\TSPK;JX4S71Y+R<E3[5VE%%,04444 %%%% !1110 4444
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M_=%9X39G7G?Q0^8^BBBNL\(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 'D8-8%_X+\/Z@6:72[;S&ZOY8R:WZ* .4L?AWX<LASIUO*<YRZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Q\0?\ D2K_ .B_
M^A"NGKF/B!_R)=_]%_\ 0A4S^%FV&_C1]4>%]NE>]^"_^17LO^N2_P J\$ZC
MOQ7O7@O'_"+V6/\ GFO\JXL+\1]!G/\ !7J=#1117>?,A1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'Q!_Y$J_^B_^A"NG
MKF/B#_R)5_\ 1?\ T(5,_A9MAOXT?5'A>>.M>]>"_P#D5[+_ *YK_*O!>W&/
M>O>_!8QX7LO^N2_RKBPOQ'T&<_P5ZG04445WGS(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y+\5>=6M@/\ GE7K5>2_%7_D+6^/^>58
M8C^&STLJ_P!ZC\SC]"_Y#EJ<XPU?0\7^J3_=%?/&A?\ (<M<?WJ^AXO]4G^Z
M*SPFS.O._BA\Q]%%%=9X04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'Q!_Y$J_^B_\ H0KI
MZYCX@_\ (E7_ -%_]"%3/X6;8;^-'U1X7T'3K7O7@K_D5[/_ *YK_*O!>@[\
MU[UX*_Y%>R]HU_E7%A?B/H,Y_@KU.AHHHKO/F0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KR7XJ\:O;'_IE7K5>2_%4XU>V_ZY5AB/X;
M/2RG_>H_,X[0N-<M1C.6KZ(B_P!4G^Z*^=]"XURU]VKZ(B_U2?[HK/"[,Z\[
M^*'S'T445UGA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7,?$'_D2K_Z+_Z$*Z>N8^(/_(E7
M_P!%_P#0A4S^%FV&_C0]4>%]NM>]>"C_ ,4O9>T2_P J\%YP>*][\%_\BO9?
M]<E_E7%A?B/H,Y_@KU.@HHHKO/F0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KR7XJ_\ (7ML_P#/*O6J\E^*O_(7ML]/*K#$?PV>EE7^
M]1^9Q^A?\ARUY_BZU]#Q?ZI/]T5\\:%_R'+;UW<5]#Q?ZI/]T5GA-F=>=_%#
MYCZ***ZSP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNP,B':U>.S0O;S/%(I5U;!!KL?A[>^1?/ QPK=!GO0!ZA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYD9- (4@;GP<^F*\B48D 'K0![9X8D\WP_:MDGY<9-:]8?A#_D6K7\?YUN4
M%%%% !1110 5Y3\0O^0XO^[_ (5ZM7E/Q"_Y#B_[O^% '.:78/J>HQ6T>3D@
MM]*]MTNPCTW3XK:)0H4<X]:\H\&?\AQ/PKV.@ HHHH **** "BBB@ K"\6_\
M@&7_ #VK=K"\6_\ ("E_SVH \7Z$\]37KG@G28K#3//5<O*.6/6O(QG)^M>V
M^&,_V!;9]* -BBBB@"M?H9-/N$'5D(%>$W<?DW<D7<&O>KC_ (]I/]TUX7JH
MQJ<X!YS0!U7P]T^*>^DN'7<47C/8UZ?7GWPWZ3\]A7H- !0>1BBB@#R3QW:Q
MVVL*(QC=DFL[PP[)X@M"#UD4'\ZU_B"[-JX!/"\#VK%\-?\ (P67IYJ_SH ]
MOHHHH **** "BBB@ J!K.W>83-"AD'1B.:GHH **K76H6ED ;FXCBSTWG%4F
M\2Z0IQ]O@/\ P.@#6H[52@U?3KH@07D,A)QA6S5V@#Q[QQ;+;^(I"G1E!/UJ
MCX9D,>OV05C\TR@_G6M\0"/^$@.?[HK'\.Y_M^PY_P"6Z_SH ]QHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D(!!!Z&EHH \\\8^ H[Q&O=+A"W '^K48!KRJ:*6"5XID*.AP01BOI
MBN2\6^#8->C\^%%2[5<*W05RU:%_>B>U@,T=.U.KMW/$@65U=#AUZ$=J]'\'
M>/C"HL]6E^48".>2:X&_T^YTJZ>WO(GC() +#&[W%5?TQWKDA.4'='N5Z%/$
MT[2U7<^F8Y$E0.C!E/0@TZO%?"?CB;1/]'O"\MMD;0.2*]ALKZWU"V6>VE61
M&'53G%>A3JJ:/E<7@JF&EKJNY9HHK#U_Q/8Z# 6GD!DQQ&#S6C:2NSFITY5)
M<L5=E[4]6M-)MFGNI0B@>O->*^)O%M_KMTZK*T=JI("H>&'8FL_7-=O=>O&G
MN9&*@D(OH*S>@STK@K5G/1;'T^!RZ-!<\]9?D)T[#'I6AI.BWVM7/D6<)8#&
MXXZ"K_AWPE?^()28T,=NI!+L.&'M7M>CZ-::+9K;VL04#DG'.:5*BYZO8K'9
MC'#KECK+\BAX:\+66@6BA(PTYY,C#YA[5T%%%>A&*BK(^6J5)5).4G=A1113
M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'X0_Y%JU_'^=;E !1110 4444 %>4_$+_D.+_N_X5ZM7E/Q"_P"0XI_V?\*
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MVZP6\81%'05/117:?/-MN["BBB@04444 %%%% !1110 4444 %%%% !1110
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M_P * */@S_D.I^%>R5XYX-_Y#J?A7L= !1110 4444 %%%% !6%XM_Y ,O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;OS[60@' 9?4>E=]8_$:TF*BYA\GU.[->?:AI5YILYAGB)([JO%4RI[H?RH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50UK_D!WW_7%OY5?
MJAK7_(#OO^N+?RH \+DX/X5Z5\-_^/"YXQ\PKS63KSZ5Z7\-_P#CQN>?XA0!
MW! (P1FJ-YI%C?J%N+=& ]!BKU% &*GA31XW#K:C(Z<UJ0VL%NH6*)% Z8%3
M44 %%%% !1110 4444 %%%% !47V>$N'\I-P[[14M% !1110 4444 '48-0K
M:P(Y=8D#'OM%344 %%%% !1110 4444 %%%% #61'&'56'N,UE7'AK2KJ8RR
MVJECZ<5KT4 9=MX=TNT??#;*"/7FM)45!A5"CV&*=10 5$+:$/O$2;CWVBI:
M* "BBB@ HHHH **** "FO&DJ[716'H1FG44 ,2*.(81%7Z#%/HHH **** "B
MBB@ HHHH **** (OLT&_=Y2;O7:*EHHH **** "HY((I?]9&K?45)10 @4*,
M* !Z"EHHH **** &O&DB[74,/0C-)'#'$,1HJ_08I]% !1110 4444 %%%%
M!1110!7N;&VNT*30JP/M67_PB.B_\^@_.MRB@"I:Z99V:;(8$4>XS5NBB@!K
M(KC#J&'H121Q1Q#$:*H]ABGT4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5#6O^0'??]<6_E5^J&M?\@.^_P"N+?RH
M \,?K^%>E?#?_CQN>?XA7FLGWOPKTKX;_P#'C<\8^84 =Q1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#=0+=6DL#?=D0J?QJ:B@#Q[5O!VI6VI"&")I(Y#A749"
M_6O1/"VAG1--\MVS*_+8K=HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10027803_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rckt-20210809.xsd" xlink:type="simple"/>
    <context id="c20210809to20210809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2021-08-09</startDate>
            <endDate>2021-08-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20210809to20210809"
      id="Fact_7a0957213d7c45a5b54cb72494c8cbc3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20210809to20210809"
      id="Fact_16da9c080de84ea8bdc42e19eac843ef">0001281895</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20210809to20210809"
      id="Fact_bc92f4ce798b499fb3b20874d5d1aa51">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20210809to20210809"
      id="Fact_653efbaf631f4ced99d4b8f70af332d8">2021-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20210809to20210809"
      id="Fact_7538917290cd408591d23ac91eb7244b">Rocket Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20210809to20210809"
      id="Fact_e2f1a4703bdf472090f7e1b57aa364db">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20210809to20210809"
      id="Fact_54d297467ecc46e58083fcf0f440bfc4">001-36829</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20210809to20210809"
      id="Fact_c92da0733544470388bab757f0643d9c">04-3475813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20210809to20210809"
      id="Fact_85e2c03e16ec443b9455c60e260d832e">9 Cedarbrook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20210809to20210809"
      id="Fact_3ee39cf79ce04e3194ad6657f9dde7a8">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20210809to20210809"
      id="Fact_924c38fb290f48e2b987254d35460d7f">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20210809to20210809"
      id="Fact_40705dc76281421584c8f80705d2c90b">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20210809to20210809"
      id="Fact_c3adc1c8d28e4022b3be15bcddb87438">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20210809to20210809"
      id="Fact_9b1a985c7e0a4f808ef977ef36ec6685">440-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20210809to20210809"
      id="Fact_c8e65d5fe52148ea86c84e1129146ade">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20210809to20210809"
      id="Fact_7b475d87d96e4ec9add72699c2acfc63">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20210809to20210809"
      id="Fact_366a687a6f21459582124d474e11dc1c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20210809to20210809"
      id="Fact_972977fe870e4d30871cc39b632848ef">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20210809to20210809"
      id="Fact_e5b2162b5aa640beaaed0ad627f1413f">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20210809to20210809"
      id="Fact_ecffefbba4a640f59ca2c7bd203a7abb">RCKT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20210809to20210809"
      id="Fact_6e8bf94bc8e1435ba86bc858cbf5a401">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20210809to20210809"
      id="Fact_bebd3a169f1e4cfa845aa75a3bc3b6c8">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140023803957112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  09,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rocket Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3475813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Cedarbrook Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-9100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001281895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCKT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R
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M4$L! A0#%     @ 8H$)4P=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !B@0E3ZPN!Q.X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !B@0E3F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &*!"5, A4N3.@0  $40   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !B@0E3GZ ;\+$"  #B#   #0              @ %]#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( &*!"5.7BKL<P    !,"   +              "
M 5D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &*!"5,<.&7J/P$  #P"   /
M              "  4(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !B
M@0E3)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !B@0E399!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10027803_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rocketpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10027803_8k.htm">brhc10027803_8k.htm</File>
    <File>brhc10027803_ex99-1.htm</File>
    <File>rckt-20210809.xsd</File>
    <File>rckt-20210809_lab.xml</File>
    <File>rckt-20210809_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10027803_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10027803_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rckt-20210809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rckt-20210809_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rckt-20210809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rckt",
   "nsuri": "http://rocketpharma.com/20210809",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027803_8k.htm",
      "contextRef": "c20210809to20210809",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://rocketpharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10027803_8k.htm",
      "contextRef": "c20210809to20210809",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-21-027552-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-21-027552-xbrl.zip
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MVN_H$BDH--Q7GXW*JROC\MI&F4S7N6]OWN6^2^\P2F8?!I.D?( &9&>>8[I
M/IKGE$FZHJL$>;J[G'(80)WV*)W9 !&VPHE8Q 'WB<\WNN0M^7$G7G*68AS$
M=:,T R7M,USG;>@"[<D]I\-B2G46KBHO@ !%= ZLO!#5*P[4Y"?5:E$)A05P
MB!GW5[>K[A"UDFP<_(Z3+%@+2!S1((J+^:D9TYQDQ2+VD!"B)$E4HTCM4A8^
M( "??4M([I7$R66^YNRT;T[#9B=S@0CIZ@'AG@RZPDA=#H>)$CB9(8JJ .F/
MHH5S*.^,L\7)9&,V*&>S[$@^8XYG73SNE:#50><5WQ.\J .,9HCQ%D&&W]'T
M59#Q9)CQ.YJH*)P^'6E\)]:8(PIU.4::E@)JE*HP:\ 7:R*G#2<3Q=]+..,>
M-G[?UJ?Y>@G?7:7E]A?\ES]JUU_G#&3-G=E]2HK/[@5BP) XANMIYK]AXOMM
MO3/(AZU#"3GVN_3P"<<4_IM:\H5"MI<%LMTC7-G[Y<_O;/? \SEYX)&G-L^Y
M%XU#OR'2/)U7=,WZT_!]/\6I$!FC0L\2W4'*U*W'8YK3XKK\#@P#X!*L2L].
M.2BRJL3A1'X^E?#R,UF[S^K;;^\6V(^XX/?'!5_B\N+5Z:>SH^M?+^??P7P)
MKEB5%_4F2N0G#I"J&^6NK3KX]>\-%J<U?XPC40+73;WFAF,>/D:GD-&Q^H*S
MC!@4URE+1S_#94COLOBB6 #HUH;2<:RYI\I?+>O)B,$XP::J5W0%!JG 1?![
MSB-?]'+@GPGHV:]@Y)\M&4020T9<#EK&TVU/<S#YWF_X;1=_-6[-RR7.O.;@
MEM/QW>U/X&UMT-/!D_P@:.^Q7L)+L<#3E_?+M/>$U3S$4UM*(']DVE@WZY)/
M="SH+;D:T,$>^7K\*GKF9?R\-ZED7B([\,<6_\FWN.Q=EO80]6(14U_KB"!$
M5%U]S.=<?<Q'J)#Q,>)PEJ?B;7NMC?DQ3P^^-F0K+3B?W^M--GF%BSE*FV<&
M+?Q;$[/?^UWYC[VHS!_Y;\'@C_\'4$L#!!0    ( &*!"5-S!%"T("H  *?"
M 0 7    8G)H8S$P,#(W.# S7V5X.3DM,2YH=&WM?6ESVTBRX/>-V/]0J^F9
MEF-!&A</R$>L+-EN=_M0V^[NF$\;!:! X@D$.#@DLS^\W_XRZP !DK(I6Y1
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M@%*%4)I+NX=R&RUG4Y9RO04D85()'02U)!B1 MJ+#^JIW\!V<0"<ZQ3%R3L
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M'\/J5YCM+SIQ+6N+XR7E-B?S^LX-,[*&?O'#?$RQFNOPEF_S/CE7S?-6 :#
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MDW%.P&JP,]L4^/>S'4Q"N)1 I[SX<K[O?.?X^)++Z_DD0Z\@%1.\'\2M*$#
MJ4@8'_6#J<)$4<:"ZZN/'RX_8?P '"31D*#A MW=/MP,4I894X6^#YY-$]!%
M*[(?^B(%221+1H"Q!<]53]$Q3 C21(Y ?R,34#FAT _&6N>],)2"OH#.QT1.
M2(N*2=B.VG%T$76-H@PFP/6]D)-;2,DTT_W@[Y1D+&60!,B$P%5OKE94L]FL
M->NTA!P9DB@.?W]]^N&<>UM)7_0AC@MK$^'+&O=\*#//W@GM]) H6 G9L%]J
MB;O=;NAF5Z:&B.VA9EQIPBE4[9-2>=7X/"PFO:E9.[W(H4Q*2M30&?L9%R>.
M8MR)/4A)O0NUFMH"2[2LP=9",=.AG;;(R"+;)1+8>C0*:&LD7D,SX1P%IG@0
MLN5#.!>::%.G;F@YF.>,IV(Y8L9L=GM^10:0(I?OGG7?#Q2;Y)E-IAL;2TC[
M@2T%[%?\3RZA991Y$RDRV+,\=CHT$&6*TRE[*AU["B+I!LM&/1@2D8/4S*2W
M+*?PW<+*R+!I6 8"V?^-Q_+\-!$@V_@U>-R](YVB6T&G]ABXX<D=UTPO'LW*
M&PN;^ "QI!_LM5@Y]^X32!EGKJ B<TI$$<+(,U2;A">HH$,5OLNP3E+GGRI(
MGOF5:]>+9(E>FNQ#4I+1:78$L%2V&[<<]0OA-U98VUG%P/K^L[O/U)V0&O&-
ML[QZUHP(R=?.C.(>>!+4D148Y??_5F0(F59^!)=<K;E*?%GMU;/]:-FOI&YN
M&\[W<5ZIF'(M%TT\5R&^<XJ"J93F;F\FH8I9]4X0 7,Z;B)@9>]:)SCFA%'5
MQ',)*)HG^%:,-O'LS6VCF=?Z6=XM3DX.(_MHV^Z^#LND7$-ARX/C-HX_GZY#
M-]:@C_&_GDZ=RT;I]_:N==H"5)]PAP3N(+:'/<Z&W['A-SCNZI1GH;07^($"
MG+5U>X:C"QQ'S;*^\1P]T*L'6,?G![O<_Z@]X:9Q9,=<-9NEOWPQ&:U48YCG
M&>%$"[FX-_W#MT.5Y:XD.69W5-_T1^3+HXI<V?^"(]+TQG_%L4K>9]FV_K#L
MDO06TO55*<0]I@JRJW]02P,$%     @ 8H$)4_.$* 6!"   <E@  !4   !R
M8VMT+3(P,C$P.# Y7VQA8BYX;6S-G&MOVS84AK\/V'_@O"\;4,>Q#0Q+T+C(
MTJ0(EB9!DF(W#(4LT8XP60PH.7'^_4A)M$7RD%(J2A8*M K/>U[>GB/)2N7W
M'S:K"#UCFH0D/AF,#PX'",<^"<)X>3)8)T,O\<-P\&'V_7?O?Q@./^$84R_%
M 9J_HO./GT[O%F'$I FZO;MAAQC]>G#(_Z#?*/$"&@9+/!SR9*;Z[YC_-?<2
MC%BG<7*\2<*3P6.:/AV/1B\O+P<OTP-"EZ/)X>%X].?GJWO_$:^\81@GJ1?[
M>("8_CC)&J^([Z79B$OIFSF-A,%TM.W+J. _#85LR)N&X\EP.C[8),&@&"(/
MU^A$R#>:OIC3^.CH:)1%MU)F%%JLM]-FJX=0OGZ41/@.+Q#_]\O=I3'[:,05
MHQBG5]X<1ZS++#U]?<(G@R1</458M#U2O(!](DJW-GQUCOCJC'_AJ_/CSGG4
M9'A+CM(#2;W(S3@S/WVL6C?-!WWM:FEM0[YVN<JLQ'$'JUSJIOF@;S$-27 >
M!^T/7.W*U>#O4X]V@(K>6?,)M#]J8*@1;[IB1U*_>)/B.,"!Z)E[6\Z=6=?9
MR39SWGH37W*-^%6$4'TZ"7/-'!/L'RS)\RC (7.>C/G!D!]DLV _?#TC[.)Y
M.D]2ZOFI<,HF<3( 8VF8\K$KL9$\4)XO#97BA*RICY4>M!%\C>;1FQ9)VN-\
M:";35<2ZY;<%.!Y^N1^@,#!I9UD3^D<T_OM^M!NU/M-3*N^+1WTQ)'98,8U"
M,?()NU@^I4-I1@M*5J9](!7+5ZQ&YG>,)!E*"3+DCEHG[B/QURL<IP_,4<$!
M"A73D$,-<"L;N:(-\#3!IDEGH@7QIOV"!JX_L:^;C%E9)2C3,]N'[ \:INR4
M>T96JW4<YC?;B4*#55-,RZ!IP!_HZ I$F[F)2'/.K @A.;9?1NV[1FHNLDPM
M*!?X6KS:Y_B>1*$?INPCZF=VPT%#+U*0,@N**4*"!OCJ=J[8-3J;P#4DS';M
M2 3VBZQECTB=595AU;6"5)-+^YC>4LSK [,ER,[T_&:7WBP6F"H(50N+R=J$
M#? UV[K"N+('$\X5B3,6'_HE <H5*)/L%_ :NTK>LOXR\.8< 7Z5:^<%<)DD
M:TQKEX%1#A<#('=7$IIY2X5AZJ=F><#I>I'DNO[6BGGKX8JQ;H^U;K1,0_48
M>FB_ADY9[P$?P47D+150P5@Q7276H!0D)U?<0Z8FR'7M;-N$>-M^V85W@50L
MGDRE)!,( KG=/8BX"!/?B_["'KU@+>JGQ J5\GA"4SEX4J%XNGYH =M7/;^
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M\$*,=<-(O06&K^QEM7IUUYV*[W LK<45.^+?_%LTA?DWY<[^!U!+ P04
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M4$L! A0#%     @ 8H$)4W,$4+0@*@  I\(! !<              ( !UA$
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2      4 !0!+ 0  ?TX

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
